Two physicians assert that pharmaceutical companies' sponsorship of clinical conferences for residents and physicians represent a conflict of interest.
The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.
Although parents may someday have the ability to enhance the complex physical and mental traits of their offspring, such genetic enhancements raise a number of difficult ethical questions.